drugset / Trial / NCT01656356

Phase I Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai Volunteers

NCT01656356 ↗

Phase 1 Completed Mahidol University

Summary

The purpose of this study is to evaluate safety and reactogenicity of live attenuated influenza H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2) manufactured by GPO, in Thailand to previously healthy Thais.

Timeline

Start
2012-05
Primary completion
2012-08
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Comparator A/17/turkey/Turkey/05/133 (H5N2) Vaccine — Intranasal

Indications